Search

Showing total 4 results
Start Over Topic business Publication Type Conference Materials Region united states Publisher cambridge university press
4 results

1. Complexifying Commodification, Consumption, ART, and Abortion.

Author

Cohen, I. Glenn

Subjects
*COMMODIFICATION, *REPRODUCTIVE technology, *ABORTION & society, *CONSUMER culture, *CONSUMERS, *SPERMATOZOA, *MEDICAL care, *BUSINESS, *ABORTION, *FERTILIZATION in vitro, *HUMAN reproductive technology, *PATIENTS, *SOCIAL skills
Abstract

This commentary on Madeira's paper complicates the relationships between commodification, consumption, abortion, and assisted reproductive technologies (ARTs) she draws in two ways. First, I examine under what conditions the commodification of ARTs, gametes, and surrogacy lead to patients becoming consumers. Second, I show that there are some stark difference between applying commodification critiques to ART versus abortion. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

2. When Worlds Collide: Medicine, Business, the Affordable Care Act and the Future of Health Care in the U.S.

Author

Wicks, Andrew C. and Keevil, Adrian A. C.

Subjects
*HEALTH care reform, *MEDICAL care, *BUSINESS & medicine, *BUSINESS models, *ECONOMICS, *BUSINESS, *COOPERATIVENESS, *MEDICAL quality control, *MEDICINE, *SOCIAL responsibility, PATIENT Protection & Affordable Care Act
Abstract

The dialogue about the future of health care in the US has been impeded by flawed conceptions about medicine and business. The present paper re-examines some of the underlying assumptions about both medicine and business, and uses more nuanced readings of both terms to frame debates about the ACA and the emerging health care environment. [ABSTRACT FROM AUTHOR]

Published
2014
Full Text
View/download PDF

3. Corruption of Pharmaceutical Markets: Addressing the Misalignment of Financial Incentives and Public Health.

Author

Gagnon, Marc-André

Subjects
*PHARMACEUTICAL industry, *MONETARY incentives, *PUBLIC health, *DRUG prices, *HEALTH, *BUSINESS models, *DRUG prescribing, *ETHICS, *ECONOMICS, *CORRUPTION, *DRUG laws, *DRUGS, *INDUSTRIES, *ORGANIZATIONS & ethics, *BUSINESS, *CLINICAL trials, *HEALTH care reform, *PHARMACEUTICAL services insurance, *LOBBYING, *MARKETING, *HEALTH policy, *PROFIT, *TAXATION, *DRUG development, *PHARMACY, *SOCIAL responsibility, *GOVERNMENT regulation, *INVESTIGATIONAL drugs, DRUGS & economics
Abstract

This paper explains how the current architecture of the pharmaceutical markets has created a misalignment of financial incentives and public health that is a central cause of harmful practices. It explores three possible solutions to address that misalignment: taxes, increased financial penalties, and drug pricing based on value. Each proposal could help to partly realign financial incentives and public health. However, because of the limits of each proposal, there is no easy solution to fixing the problem of financial incentives. [ABSTRACT FROM AUTHOR]

Published
2013
Full Text
View/download PDF